Objective: This study investigated, in isolated human internal mammary artery, the involvement of the cyclooxygenase and the lipoxygenase pathways of arachidonic acid metabolism in the contraction induced by angiotensin II. Methods: Rings of human internal mammary arteries were suspended in organ baths for recording of isometric tension. In addition, the release of eicosanoids in response to angiotensin II (0.3 mM) was measured by enzyme immunoassay. Results: In human arterial rings without endothelial dependent relaxation in response to substance P or acetylcholine, the angiotensin II-induced contractions were significantly (P,0.05) reduced by 27% in the presence of GR32191 0.3 mM (thromboxane A (TXA ) receptor antagonist) but remained unchanged in the presence of 2 2 dazoxiben 100 mM (thromboxane synthase inhibitor). In addition, angiotensin II failed to modify TXB and 6-keto-PGF production.
Introduction angiotensin-II stimulates synthesis and release of many different eicosanoids from a variety of cells and tissues. Angiotensin-II-mediated vasoconstriction is involved in
This action is primarily the consequence of phospholipase both the physiological maintenance of arterial pressure and activation resulting in the formation of free arachidonic the pathogenesis of various forms of experimental and acid available for metabolism by oxygenases. human hypertension. It is now well documented that
The modulation of angiotensin-II-induced contractions by cyclooxygenase products has been well documented in various animal models. Angiotensin II stimulated PGI and 
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0008-6363 / 00 / $ -see front matter © 2000 Published by Elsevier Science B. V. PII: S0008-6363( 00 )00112-7 from aortic rings [4, 5] as well as thromboxane A (TXA ) pentahydrate (30.0 mM), adenosine (5.0 mM), allopurinol 2 2 release from aortic rings [5] [6] [7] . In normotensive rats, (1.0 mM), total glutathione (3.0 mM). The IMA were infusion of angiotensin II stimulated the production of carefully dissected free from the surrounding connective PGI , PGE and TXA [4, 8] and administration of a TXA tissue and cut into 3-mm length rings. The rings were then 2 2 2 2 receptor antagonist markedly attenuated the short-term used in experiments to examine the effects of angiotensin pressor response to angiotensin II [8] . In rats with an-II on isometric tension development and to evaluate the giotensin II-salt-induced-hypertension, TXA production vascular release of eicosanoids. 2 was increased [5] decreased blood pressure. IMAs In addition to the cyclooxygenase products, lipoxygenase metabolites contribute to the vasoconstrictor action of
The rings were mounted on parallel wires and placed in angiotensin II [9] [10] [11] . Lipoxygenases catalyze the formaa 10-ml organ bath filled with Krebs solution maintained at tion of 5-,12-or 15-HPETEs, which are subsequently 378C and gassed with a mixture of 5% CO , 95% O . The 2 2 transformed to the corresponding HETEs and in the case of Krebs solution had the following composition: NaCl 5-HETE to leukotrienes. 5-and 12-Lipoxygenase in-(118.0 mM), KCl (4.7 mM), CaCl (2.5 mM), MgSO 2 4 hibitors have been reported to reduce the constrictor effect (1.0 mM), KH PO (1.0 mM), glucose (11.0 mM), 2 4 of angiotensin II on isolated vessels [9] [10] [11] [12] , the pressor NaHCO (25.0 mM). The lower wire was fixed to a 3 effects of angiotensin II in normotensive rats [12] and the micrometer (Mitutoyo, Japan) and the upper wire was blood pressure in rats with spontaneous hypertension [13] attached to a force transducer (UF-1, Pioden, UK) to allow as well as in rats with renovascular hypertension [14] .
changes in tension to be recorded isometrically. Changes Most of the data on the functional involvement of in tension were monitored on Linseis recorder (Bioblock, eicosanoids in angiotensin-II-mediated vascular effects are France). Each ring of IMA was set up under an initial derived from in vivo and in vitro studies in animal models.
tension of 5 g as previously described [15] and allowed to Therefore, the aim of the present study was to assess the equilibrate for 60 min, the Krebs solution being changed involvement of the cyclooxygenase and the lipoxygenase every 15 min. The rings were then challenged twice by the pathways of arachidonic acid metabolism in the vasoconaddition of 90 mM KCl. These initial maximal contracstrictor response to angiotensin II in human internal tions were performed to stabilize the preparations and mammary artery (IMA).
ensure reproducible contractile responsiveness. Absolute values of the second contractions elicited by 90 mM KCl were 2.560.1 g (n5109). The arterial rings were then 2. Methods submaximally precontracted with 3 mM of norepinephrine. After contraction had stabilized, the preparations were 2.1. Tissue preparation exposed to either acetylcholine (1 mM) or substance P (1 mM) to assess endothelial function. None of the prepara-IMA segments were harvested from 58 patients undertion tested relaxed to acetylcholine or substance P. Howgoing IMA coronary artery graft surgery. The investigation ever, we have recently performed histological examination conforms with the principles outlined in the Declaration of which revealed an intact endothelium on the IMA [16] . Helsinki and was approved by the Medical Ethics CommitTherefore, we conclude that the lack of clear-cut relaxation tee of the Academic Medical Hospital. Among the patients, to acetylcholine or substance P was related to endothelial 33% had hypertension, 70% had hypercholesterolemia and dysfunction. The ring was then washed four times with 20% had diabetes mellitus. The preoperative drug therapy Krebs solution to restore the baseline tension and during in these patients was as follows: 25% were on calcium the following h, the Krebs solution was changed every 15 blockers, 70% on b-adrenoceptor blockers, 15% on potasmin. sium channels openers, 25% on angiotensin converting Cumulative concentration-response curves were conenzyme inhibitors, 70% on nitrates and 37% on hydroxylstructed for angiotensin II (0.5 log increments, 10 pM-0.3 methyl CoA reductase inhibitors. mM). The contribution of prostanoids was assessed by The IMAs were removed together with their pedicle prior incubations of the preparations with either the including two satellite veins and the surrounding fat tissue cyclooxygenase inhibitor indomethacin (1 mM for 30 min), and the discarded distal IMA segments were obtained prior the potent and selective TXA / PGH receptor antagonist 2 2 to anastomosia. The vessel samples were immediately GR32191 (0.3 mM for 45 min) [17] or the selective placed in oxygenated Belzer solution maintained at 148C, thromboxane synthase inhibitor dazoxiben (100 mM for 60 and transported to the laboratory where they were stored at min) [18] . 48C and used within 24 h. The composition of the Belzer
The contribution of lipoxygenase-derived eicosanoids solution was: hydroxyethyl starch (5.0 mM), potassium was assessed by prior incubation with either the dual lactobionate (100.0 mM), KHPO (28.5 mM), raffinose cyclooxygenase and lipoxygenase inhibitor phenidone (10 mM for 30 min) [19] , the inhibitor of the 5-, 12-and preparations tested. Analysis of variance (ANOVA) for 15-lipoxygenases, baicalein (100 mM for 30 min) [20, 21] , repeated measures was performed, followed by Bonferroni the selective 5-lipoxygenase inhibitor AA861 (10 mM for corrected t-test. Individual comparisons were made by 30 min) [22] for 60 min at 378C, the Krebs solution being changed the 15(S)-HETE [15(S)-hydroxyeicosa-5Z,8Z,13E-tetraevery 15 min. The ring vessels were then incubated with enoic acid] were purchased from Cayman. All drugs were either angiotensin II (0.3 mM, 30 min), indomethacin (1 dissolved in distilled water excepted indomethacin, mM, 30 min), indomethacin (1 mM) plus angiotensin II baicalein and phenidone. Stock solutions of indomethacin (0.3 mM) (indomethacin added 30 min before angiotensin (0.1 mM) were prepared in ethanol and stock solutions of II) or solvents (basal release of eicosanoids). The Krebs baicalein (1 mM) and phenidone (10 mM) were prepared solution was collected and samples were frozen at 2808C.
in dimethylsulfoxide. The subsequent dilutions were perThe rings were dried in an oven for measurement of dry formed in distilled water for indomethacin and in diweight. The levels of TXA (measured as TXB ), PGI methylsulfoxide for baicalein and phenidone. The final 2 2 2 (measured as 6-keto-PGF ) and cysteinyl leukotrienes concentrations of the solvents were 0.001% ethanol in the 1a were determined by enzyme immunoassay on unextracted indomethacin experiments and 1% dimethylsulfoxide in samples using reagents purchased from Cayman (Ann the phenidone and baicalein experiments. These final Arbor, USA). The detection limits of the assays were 3.2, concentrations of solvents did not alter the response to 13.3 and 15.0 pg / ml and the EC values (50% B / B0) angiotensin II.
50
were 36.6, 50.6 and 39.0 pg / ml for the cysteinyl leukotrienes, TXB and 6-keto PGF immunoassays, respec-
tively. In addition, the intra-and inter-assay coefficients of 3. Results variation were ,10%. The results are expressed as picograms of eicosanoids per milligram of tissue dry weight.
Measurement of isometric tension in rings of IMA

Analysis of results
Angiotensin II-induced concentration-dependent contractions of IMA. In terms of efficacy and potency, the Concentrations referred to final organ bath concentraresponses to angiotensin II displayed a variability, which tions. Contractile responses were expressed as a percentage was not significantly different among the control groups of the contraction induced by the second KCl (90 mM) ( Table 1) . Incubation of IMA rings with either inchallenge. The concentration of agonist producing 50% of domethacin, GR32191 and dazoxiben resulted in slow the maximal effect (EC ) was determined from each decreases of the basal tone which at the end of the domethacin, inhibited by GR32191 and was not modified by dazoxiben (Fig. 1, Table 1 ). Since dazoxiben did not alter angiotensin II-induced contractions whereas GR32191 inhibited the response to angiotensin II, the effect of GR32191 was assessed in presence of indomethacin to check whether its inhibitory effect was due to the blockade of a cyclooxygenase product acting on the TXA / PGH 2 2 receptors. In presence of indomethacin, GR32191 did not inhibit angiotensin II-induced contraction, the pD and 2 E values being, respectively 9.160.7 and 98.3622.3% max for the control rings (n55) and 9.160.4 and 87.1615.6% for the rings pretreated by indomethacin plus GR32191 (n55). Incubation of IMA rings with either phenidone, baicalein, AA861 and MK571 resulted in slow decreases of the basal tone which at the end of the incubation period were, respectively 0.2060.06 g (n56), 0.4160.22 g (n5 6), 0.1460.06 g (n55) and 0.0360.06 g (n58).
The dual cyclooxygenase and lipoxygenase inhibitor, phenidone, decreased the maximal response to angiotensin II but did not alter its potency (pD ) (Fig. 2a, Table 1 ). 2 Baicalein, at a concentration which has been reported to inhibit 5-, 12-and 15-lipoxygenases [20, 21 ] also decreased (Fig. 2b, Table 1 ). Pretreatment with inangiotensin II in human IMA rings. Data are expressed as percentages of angiotensin II (Fig. 3a , Table 1 ). In addition, the potent and specific CysLT receptor antagonist MK571 inhibited 1 the maximal response to angiotensin II (Fig. 3b, Table 1 ). PGF and TXB ( The contractile effects of the four leukotrienes were tested contrast, angiotensin II induced a 1.5-fold significant in different preparations (n54-5 for each leukotriene).
increase in cysteinyl-leukotriene release from the IMA LTB and LTE (up to 0.1 mM) did not cause contraction rings (Table 2 ). In the presence of indomethacin, the 4 4 of the IMA. LTC elicited a weak and variable contraction release of cysteinyl leukotrienes after angiotensin II chal-4 (E : 5.561.9%) and LTD induced a concentrationlenge was potentiated whereas the levels of 6-keto-PGF max 4 1a dependent contraction with a pD of 7.660.4 and a and TXB remained unchanged (Table 2) . 2 2 maximal response at 0.1 mM of 38.8615.5%, respectively (n55) (Fig. 4) . MK571 totally abolished the response to LTD (n53). 15-HPETE) [27] . However, the observation that indomethacin abolished the inhibitory effect of GR32191 on the response to angiotensin II suggests that the TP receptor agonist involved in angiotensin II-induced contractions is a metabolite of the cyclooxygenase pathway, although a non specific functional antagonism between GR32191 and indomethacin can not be ruled out. In addition, the possible contribution of 15-HETE appears unlikely given the lack of contractile effect of 15-HETE. Evidence in the literature supported the involvement of PGH in the response to 2 angiotensin II in animal models [6, 7] . Moreover, it has recently been shown on rat vascular smooth muscle cells that angiotensin II induced the expression of cyclooxygenase-2 within 1 h [28] . With respect to the timing of our experiments, (angiotensin II concentrationresponse curves lasting 30-40 min), the involvement of prostanoids (mainly PGH ) in angiotensin II contractile 2 response may reflect the stimulation of either cyclooxy- induce an increase in the in vitro release of 6-keto PGF , The human IMA used in this study were devoid of solution for 24 h did not significantly alter the release of functional endothelium inasmuch as no relaxation was PGI in response to arachidonate, acetylcholine and cal-2 observed in response to either acetylcholine or substance P. cium ionophore on rabbit aorta [29] . In fact, angiotensin However, since the contractile response to angiotensin II II-mediated production of PGI appears variable among 2 was not altered by endothelium removal in human IMA different animal vascular preparations [1, 3, 30, 31] . In our [25] , the absence of functional endothelium may not preparations of human IMA, the absence of release of PGI 2 interfere with the conclusions and the clinical relevance of in response to angiotensin II suggests that the enhanced the study.
Discussion
angiotensin II-induced contraction in the presence of The involvement of arachidonic acid metabolites acting indomethacin is not due to inhibition of the release of this on TXA / PGH receptors in the contractile response to relaxant prostaglandin. This potentiating effect of in- 2 2 angiotensin II is suggested by the inhibitory effect of domethacin is in line with the rise in pressure in response GR32191. However, TXA may not be involved in the to angiotensin II in vitro on human placental cotyledon 2 contractile responses to angiotensin II since thromboxane [11] . In human IMA, indomethacin has been reported to synthase inhibition with dazoxiben did not modify anenhance the maximal contractile response to angiotensin II giotensin II-induced contractions. Furthermore, angiotensin by 60% although this increase did not reach significance, II, at a concentration which induced a maximal contractile probably since the low number of arterial rings tested [32] . response in organ bath, did not produce TXA . These In addition, indomethacin induced an increase in the 2 results allowed the conclusion that a TP receptor agonist, release of cysteinyl leukotrienes from IMA rings in other than TXA , is involved in angiotensin II-induced response to angiotensin II, suggesting that the enhanced 2 contractions. The other agonists of the TP receptors response to angiotensin II in presence of indomethacin may have been due to a redirection of arachidonic acid lesser degree, LTC elicited contraction of the IMA rings. 4 metabolism from the cyclooxygenase pathway to the These data are similar to previous results obtained on the lipoxygenase pathway. same vascular preparation [37] . In addition, angiotensin II Phenidone is a dual cyclooxygenase and lipoxygenase induced the release of cysteinyl leukotrienes from IMA inhibitor and has previously been shown to inhibit the rings supporting the direct involvement of these 5-lipoxycontractile response to angiotensin II in rat femoral artery genase metabolites in the contractile response to angiorings [12] . Since selective cyclooxygenase blockade with tensin II. These data demonstrate the participation of the indomethacin enhanced the angiotensin II contractile recysteinyl leukotrienes in the vascular response to angiosponse in the present study, the attenuation of the contractensin II. In addition, MK571, a selective CysLT receptor 1 tile response by phenidone may be ascribed to the lipoxyantagonist, abolished the contraction induced by LTD and 4 genase inhibitory activity of this agent and not to its reduced the response to angiotensin II. Since the contraccyclooxygenase blocking property. Baicalein, a potent tile response to angiotensin II in IMA is not modulated by inhibitor of the 5-, 12-and 15-lipoxygenases [20, 21] sponse of IMA to angiotensin II. Such an inhibitory effect raphy on the tunica media of human IMA but not on the of baicalein has been previously reported in rat femoral endothelium [37] , our results suggest that the cysteinyl artery [12] . The involvement of 15-lipoxygenase derivaleukotrienes (particularly LTD ), released in response to 4 tives acting by direct activation of TP receptors appears angiotensin II, participated in the vasoconstriction to this less likely in the human IMA preparation since the results vasoactive peptide by acting mainly on CysLT receptors 1 with indomethacin and GR32191 and the absence of located on the smooth muscle. contractile effect of 15-HETE. Collectively, these data
In conclusion, this study suggests that the in vitro support the involvement of 5-or 12-lipoxygenase metabovasoconstrictor effects of angiotensin II in human IMA is lites in the contraction of IMA in response to angiotensin mediated at least in part by eicosanoids produced by the II. 12-Lipoxygenase is expressed in human aortic smooth cyclooxygenase pathway, probably PGH acting on TP 2 muscle cells [33] and angiotensin II increases 12-HETE receptors, and by the lipoxygenase pathway, notably LTD 4 release from human perfused placental cotyledon as well acting on CysLT receptors. 1 as from cultured umbilical artery smooth muscle cells [11] . 12-HETE is generally produced as stereoisomers by 12-lipoxygenase and cytochrome P-450 which produce 12(S)
